WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 3, 2020-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on January 31, 2020 the compensation committee of the Company’s board of directors granted a
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2020 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 2, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 30, 2020 the compensation committee of the Company’s Board of Directors granted a
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 1, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 29, 2022 , the compensation committee of the Company’s Board of Directors approved grants
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 5, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on March 31, 2022 , the compensation committee of the Company’s Board of Directors approved grants of
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 1, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on August 31, 2020 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 3, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2022 , the compensation committee of the Company’s Board of Directors approved
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 3, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2021 the compensation committee of the Company’s Board of Directors granted a
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 22, 2021 the compensation committee of the Company’s Board of Directors granted